SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
neutropenia (58%) and thrombocytopenia (55%); grade 3/4 nonhematologic TRAEs were uncommon;
12 patients (36%) had serious treatment-emergent AEs (TEAEs); 2 patients had fatal AEs (sepsis study-treatment
related and myeloma progression 1 patient; general physical health deterioration).
Bortezomib arm: Median age was 71 years (range, 61-82); median number of prior LoTs was 2.5 (range,
1-4); 40% had high-risk cytogenetics; 70% were refractory to last LoT; 30% received prior frontline
ASCT; and 90% received a prior PI. Median treatment duration was 5.6 months (range, 1.4-22.8); 7
patients (70%) remained on treatment; 3 patients discontinued (PD, n=2; lack of efficacy, n=1). ORR
was 60%. Most common grade 3/4 TRAEs were thrombocytopenia (80%) and neutropenia (60%); grade
3/4 nonhematologic TRAEs were uncommon; 6 patients (60%) had serious TEAEs. No dose-limiting
toxicities or fatal AEs reported.
Conclusion: Melflufen plus dexamethasone in triplet combination with daratumumab or bortezomib
has encouraging activity and was well tolerated in RRMM. This analysis of the daratumumab arm in
more patients with longer follow-up suggests consistent responses with continued therapy.